Get started
Author

Stephen L. DeWall

Observed names: S. DeWall, S. Dewall, Stephen DeWall
ORCID: 0000-0002-8119-5748
Observed ORCID: 0000-0002-8119-5748
OpenAlex ID: A5042823676
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
2022 · Tong-yuan Yang, Manuela Braun, et al. · Molecular Therapy — Methods & Clinical Development · 128
PDF
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
2017 · Vincent Meininger, Angela Genge, et al. · The Lancet Neurology · 84
PDF
A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus
2016 · Elizabeth A. McKie, Juliet L. Reid, et al. · PLoS ONE · 80
PDF
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin- 18 mAb GSK1070806 in healthy and obese subjects
2014 · Prafull Mistry, Juliet Reid, et al. · International Journal of Clinical Pharmacology and Therapeutics · 41
Neutralizing Antibody Validation Testing and Reporting Harmonization
2023 · Heather Myler, João Pedras-Vasconcelos, et al. · The AAPS Journal · 33
PDF
False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay
2013 · Keguan Chen, Jerry G. Page, et al. · Journal of Immunological Methods · 33
First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation
2016 · Adam D. Cohen, Rakesh Popat, et al. · Blood · 29
A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function
2021 · E. Wlodek, R. B. Kirkpatrick, et al. · PLoS ONE · 26
PDF
Immunogenicity Risk Assessment for PEGylated Therapeutics
2020 · Johanna R. Mora, Joleen T. White, et al. · The AAPS Journal · 22
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
2026 · Timothy A. Yap, Randy F. Sweis, et al. · Nature Medicine · 14
PDF
Toward Reference Intervals of ARSA Activity in the Cerebrospinal Fluid: Implication for the Clinical Practice of Metachromatic Leukodystrophy
2020 · Francesco Morena, Chiara Argentati, et al. · The Journal of Applied Laboratory Medicine · 10
Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study
2021 · Karen Liao, Keguan Chen, et al. · PLoS ONE · 8
PDF
Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody
2011 · Karen Liao, Dan Sikkema, et al. · Journal of Immunological Methods · 8
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
2024 · Nicholas I Paton, Meera Gurumurthy, et al. · The Journal of Infectious Diseases · 6
Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159
2018 · E.J. Dettman, Fabio Rigat, et al. · Blood · 6
780 SRK-181, a latent TGFβ1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors
2022 · Timothy Yap, Justin Gainor, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)
2023 · T.A. Yap, J. Gainor, et al. · ESMO Open · 1
PDF
Investigating mechanisms of resistance to immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC).
2026 · Soki Kashima, David A. Braun, et al. · Journal of Clinical Oncology
812 DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor resistant advanced cancers
2024 · Timothy A Yap, Randy Sweis, et al. · Journal for ImmunoTherapy of Cancer
726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study
2023 · Susan Henry, Stephen DeWall, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 20
Citation count: 531
H-index: 10
I10-index: 11
Year
Topic
Type